Sigma-1 Receptor (Sigmar1)

Sigma-1 Receptor (Sigmar1)

<div class="infobox infobox-protein">

| Property | Value |
|----------|-------|
| Protein Name | Sigma-1 Receptor |
| Gene | SIGMAR1 |
| UniProt ID | Q9Y6M5 |
| PDB ID | 5HK1, 5HI4, 6DJZ, 7MC6 |
| Molecular Weight | ~25 kDa (223 amino acids) |
| Subcellular Localization | Endoplasmic reticulum, mitochondrial membrane |
| Protein Family | Sigma receptor family, chaperone family |

</div>

Overview

The sigma-1 receptor (Sigmar1) is a unique transmembrane chaperone protein predominantly localized to the endoplasmic reticulum (ER) and mitochondrial membranes[@hayashi2007]. It functions as a ligand-operated chaperone that modulates calcium signaling, ER stress responses, and mitochondrial function. Mutations in SIGMAR1 cause a rare form of juvenile-onset amyotrophic lateral sclerosis (ALS) and distal motor neuropathy, while common variants are associated with increased risk for sporadic ALS and frontotemporal dementia (FTD)[@alsaif2011]. This page covers Sigmar1 structure, normal neurological functions, disease mechanisms, and therapeutic potential.

Structure

The sigma-1 receptor is a 223-amino acid integral membrane protein[@hayashi2007]:

Domain Organization

• N-terminal region (residues 1-50): Proline-rich, involved in protein interactions
• Transmembrane domains (residues 51-80, 90-120): Two transmembrane helices
• Ligand-binding domain (residues 80-160): Hydrophobic pocket for agonist binding
• C-terminal region (residues 160-223): Chaperone domain, Ca²⁺ binding

...

Sigma-1 Receptor (Sigmar1)

<div class="infobox infobox-protein">

| Property | Value |
|----------|-------|
| Protein Name | Sigma-1 Receptor |
| Gene | SIGMAR1 |
| UniProt ID | Q9Y6M5 |
| PDB ID | 5HK1, 5HI4, 6DJZ, 7MC6 |
| Molecular Weight | ~25 kDa (223 amino acids) |
| Subcellular Localization | Endoplasmic reticulum, mitochondrial membrane |
| Protein Family | Sigma receptor family, chaperone family |

</div>

Overview

The sigma-1 receptor (Sigmar1) is a unique transmembrane chaperone protein predominantly localized to the endoplasmic reticulum (ER) and mitochondrial membranes[@hayashi2007]. It functions as a ligand-operated chaperone that modulates calcium signaling, ER stress responses, and mitochondrial function. Mutations in SIGMAR1 cause a rare form of juvenile-onset amyotrophic lateral sclerosis (ALS) and distal motor neuropathy, while common variants are associated with increased risk for sporadic ALS and frontotemporal dementia (FTD)[@alsaif2011]. This page covers Sigmar1 structure, normal neurological functions, disease mechanisms, and therapeutic potential.

Structure

The sigma-1 receptor is a 223-amino acid integral membrane protein[@hayashi2007]:

Domain Organization

• N-terminal region (residues 1-50): Proline-rich, involved in protein interactions
• Transmembrane domains (residues 51-80, 90-120): Two transmembrane helices
• Ligand-binding domain (residues 80-160): Hydrophobic pocket for agonist binding
• C-terminal region (residues 160-223): Chaperone domain, Ca²⁺ binding

Structural Features

• Transmembrane architecture: Type III membrane protein with two transmembrane helices
• Ligand binding: Binds a variety of ligands including (+)-pentazocine, SA4503, and [donepezil](/entities/donepezil)
• Oligomerization: Forms homodimers and higher-order oligomers
• Ca²⁺ binding: C-terminal domain binds Ca²⁺ with moderate affinity
• PDZ-binding motif: C-terminal PDZ-binding sequence for protein interactions

Normal Function in the Nervous System

Chaperone Activity

• ER chaperone function: Helps fold and regulate ER-resident proteins[@hayashi2007]
• Protein quality control: Targets misfolded proteins for degradation
• Calcium homeostasis: Modulates ER Ca²⁺ store release

Mitochondrial Function

• Mitochondrial dynamics: Regulates mitochondrial fission and fusion[@hayashi2007]
• Bioenergetics: Maintains mitochondrial membrane potential
• Mitochondrial calcium: Modulates mitochondrial Ca²⁺ uptake

Neuroprotection

• ER stress response: Activates [UPR](/entities/unfolded-protein-response) signaling pathways[@matsumoto2016]
• [Autophagy](/entities/autophagy) induction: Promotes clearance of protein aggregates
• Anti-apoptotic signaling: Blocks caspase activation

Neuronal Signaling

• Ion channel modulation: Regulates NMDA, potassium, and calcium channels
• Neurotransmitter systems: Modulates dopamine, serotonin, and glutamate signaling
• Synaptic plasticity: Involved in [LTP](/mechanisms/long-term-potentiation) and memory formation

Lipid Metabolism

• Lipid raft organization: Associates with lipid rafts
• Sphingolipid synthesis: Involved in ceramide metabolism
• Membrane remodeling: Regulates membrane protein trafficking

Role in Neurodegenerative Diseases

Amyotrophic Lateral Sclerosis (ALS)

Genetics

SIGMAR1 mutations cause a rare form of juvenile-onset ALS[@alsaif2011]:

• Autosomal recessive inheritance
• E102Q mutation: Most common pathogenic variant
• Onset: Typically in second or third decade
• Phenotype: Progressive limb weakness, motor neuropathy

Pathogenic Mechanisms

Loss of chaperone function

• Impaired ER stress response
• Accumulation of misfolded proteins
• Disrupted protein quality control

Mitochondrial dysfunction

• Impaired mitochondrial Ca²⁺ handling
• Reduced ATP production
• Increased [ROS](/entities/reactive-oxygen-species) production

Calcium dysregulation

• Disrupted ER-mitochondria contact sites
• Altered Ca²⁺ signaling
• Excitotoxicity susceptibility

Autophagy impairment

• Reduced autophagic flux
• Protein aggregate accumulation
• Impaired mitophagy

Frontotemporal Dementia (FTD)

• Genetic association: Common variants increase FTD risk
• [TDP-43](/mechanisms/tdp-43-proteinopathy) pathology: Often co-occurs with TDP-43 inclusions
• Overlap with ALS: SIGMAR1 is an ALS-FTD gene

Other Neurodegenerative Diseases

• Alzheimer's disease: Altered expression in AD brains
• Parkinson's disease: Potential role in dopaminergic neuron survival
• Huntington's disease: Modulates mutant [huntingtin](/proteins/huntingtin) toxicity

Therapeutic Targeting

Drug Development

Sigma-1 Receptor Agonists

• SA4503: Selective agonist, neuroprotective in preclinical models[@ono2003]
• PRE-084: Selective agonist, improves mitochondrial function
• Donepezil: Approved AD drug with Sigmar1 agonist activity
• Fluvoxamine: SSRI with Sigmar1 binding

Mechanisms of Neuroprotection

ER stress mitigation

• Activates chaperone pathways
• Reduces pro-apoptotic signaling
• Promotes protein folding

Mitochondrial protection

• Maintains mitochondrial function
• Reduces ROS
• Preserves ATP levels

Calcium homeostasis

• Modulates ER-mitochondria coupling
• Reduces excitotoxicity
• Protects against Ca²⁺ dysregulation

Anti-inflammatory effects

• Reduces microglial activation
• Modulates neuroinflammation

Clinical Trials

• Donepezil: FDA-approved for AD, secondary Sigmar1 effects
• Cutamesine (SA4503): Completed phase II for ALS
• Novel agonists: Several in preclinical development

Gene Therapy Approaches

• Viral delivery: AAV vectors for SIGMAR1 overexpression
• Small molecules: [Blood-brain barrier](/entities/blood-brain-barrier) permeable agonists
• Combination therapy: Sigmar1 agonists with other neuroprotective agents

Key Publications

[Hayashi, T. & Su, T.P. (2007) Sigma-1 receptor chaperones at the ER-mitochondria interface (Journal of Cell Biology)](https://doi.org/10.1083/jcb.200611132)

[Al-Saif, A. et al. (2011) A mutation in sigma-1 receptor causes juvenile amyotrophic lateral sclerosis (Annals of Neurology)](https://doi.org/10.1002/ana.22271)

[Matsumoto, R.R. et al. (2016) Sigma receptors: Potential targets for Parkinson's disease (Neuroscience & Biobehavioral Reviews)](https://doi.org/10.1016/j.neubiorev.2016.08.014)

[Ono, Y. et al. (2003) Neuroprotective effects of sigma-1 receptor ligands (Brain Research)](https://doi.org/10.1016/S0006-8993(03)02638-9)

Cross-References

• [SIGMAR1 Gene](/genes/sigmar1) — Gene encoding sigma-1 receptor
• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis) — Primary disease
• [Endoplasmic Reticulum Stress](/mechanisms/endoplasmic-reticulum-stress) — ER stress pathway
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction) — Mitochondrial mechanisms
• [ALS Therapeutics](/therapeutics/als-therapeutics) — Treatment options

See Also

• [TDP-43](/mechanisms/tdp-43-proteinopathy)
• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
• [Endoplasmic Reticulum Stress](/mechanisms/endoplasmic-reticulum-stress)
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

[Unknown, Hayashi, T. & Su, T.P. (2007) Sigma-1 receptor chaperones at the ER-mitochondria interface (Journal of Cell Biology) (2007)](https://doi.org/10.1083/jcb.200611132)

[Al-Saif, A. et al., (2011) A mutation in sigma-1 receptor causes juvenile amyotrophic lateral sclerosis (Annals of Neurology) (2011)](https://doi.org/10.1002/ana.22271)

[Matsumoto, R.R. et al., (2016) Sigma receptors: Potential targets for Parkinson's disease (Neuroscience & Biobehavioral Reviews) (2016)](https://doi.org/10.1016/j.neubiorev.2016.08.014)

[Ono, Y. et al., (2003) Neuroprotective effects of sigma-1 receptor ligands (Brain Research) (2003)](https://doi.org/10.1016/S0006-8993(03)